Remove Exercise Remove Preserved Ejection Fraction Remove Pulmonary
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction

American College of Cardiology

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

article thumbnail

Diastolic exercise stress testing in heart failure with preserved ejection fraction: The DEST?HF study

European Journal of Heart Failure

Haemodynamic curve morphology is displayed for right atrial (RAP), right ventricular (RVP), mean pulmonary artery (PAP), and pulmonary capillary wedge pressure (PAWP). ΔPAWP: difference of PAWP between rest and peak exercise. The primary outcome was the difference (Δ) between resting and exercise PAWP in each modality.

article thumbnail

Right Ventricular?Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. The patients underwent invasive cardiac catheterization and simultaneous echocardiography at rest and during exercise.

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.

article thumbnail

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

DAIC

RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF).

article thumbnail

The Politics of HFpEF—What’s Good for the Left Is Good for the Right

JAMA Cardiology

Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.